Jun 21, 2026 5:00 pm EDT Definium Therapeutics to Discuss Topline Results from Phase 3 Emerge Study in Major Depressive Disorder on June 22, 2026
May 21, 2026 7:00 am EDT Definium Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
May 12, 2026 7:00 am EDT Definium Therapeutics Announces First Patient Dosed in Ascend, the Second Phase 3 Pivotal Study of DT120 ODT in Major Depressive Disorder
May 7, 2026 4:01 pm EDT Definium Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
Apr 30, 2026 4:01 pm EDT Definium Therapeutics to Report First Quarter 2026 Financial Results on May 7, 2026
Apr 22, 2026 4:15 pm EDT Definium Therapeutics Highlights DT120 ODT (Lysergide Tartrate) Clinical Advancements and Commercial Strategy at Investor and Analyst Day